Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Waymade-Trientine trientine hydrochloride Wilson's Disease Reimburse with clinical criteria and/or conditions Complete
Wakix pitolisant hydrochloride Narcolepsy Do not reimburse Complete
Vyzulta latanoprostene bunod Open-angle glaucoma or ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Vyvgart efgartigimod alfa Generalized myasthenia gravis (gMG) Reimburse with clinical criteria and/or conditions Active
Vyvanse Lisdexamfetamine dimesylate Attention deficit hyperactivity disorder Do not list Complete
Vyndaqel tafamidis transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Vyndaqel tafamidis Transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete
Vyepti eptinezumab Migraine Reimburse with clinical criteria and/or conditions Complete
Vyalev foslevodopa foscarbidopa Parkinson's disease Reimburse with clinical criteria and/or conditions Complete